ReShape Lifesciences Inc (RSLS) Actualités

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

IRVINE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier...

Form 8-K - Current report

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

IRVINE, Calif. and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq:...

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 8-K - Current report

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form S-4/A - Registration of securities, business combinations: [Amend]

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

Revenue Increased 16.6% in the Third Quarter of 2024 Over the Second Quarter, Representing the Third Sequential...